SCHEMBL24913406

SCHEMBL24913406

CCSc1cc(=O)c2cc(C)cc([C@@H](C)N)c2o1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 9/20 0.37
▸ PIK3CB P42338 3/20 0.35
▸ PIK3CD O00329 2/20 0.35
▸ PIK3CG P48736 2/20 0.35
▸ PRKDC P78527 2/20 0.34
▸ MAPT P10636 2/20 0.33
▸ ELANE P08246 1/20 0.33
▸ CCNE2 O96020 1/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ CDK4 P11802 1/20 0.33
▸ CCNB1 P14635 1/20 0.33
▸ CCND1 P24385 1/20 0.33
▸ CCNE1 P24864 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ CSNK2A2 P19784 4/20 0.33
▸ CSNK2B P67870 4/20 0.33
▸ CSNK2A1 P68400 4/20 0.33
▸ THRB P10828 2/20 0.32
▸ ATM Q13315 1/20 0.31
▸ MTOR P42345 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23887343 1.00 PIK3CA (0.37) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL30064040 0.87 PIK3CA (0.39) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL23887207 0.87 PIK3CA (0.37) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL23887051 0.87 PIK3CA (0.39) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL23887389 0.86 CCNE2 (0.33) PIK3CAPIK3CBPIK3CDPIK3CGCCNE2
SCHEMBL30770658 0.83 PIK3CA (0.34) PIK3CACCNE2CDK1CDK4CCNB1
SCHEMBL23887281 0.83 PIK3CA (0.34) PIK3CACCNE2CDK1CDK4CCNB1
SCHEMBL30770733 0.82 PIK3CA (0.34) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL29202685 0.82 PIK3CA (0.34) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC
SCHEMBL29202702 0.81 PIK3CA (0.34) PIK3CAPIK3CBPIK3CDPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119301106-A Allosteric benzopyrone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease 佩特拉制药公司 2025-01-10 — — CN disclosed
CN-117769546-A Allosteric ketene inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease 佩特拉制药公司 2024-03-26 — — CN disclosed
CN-117693506-A Allosteric ketone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease 佩特拉制药公司 2024-03-12 — — CN disclosed
US-11878970-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2024-01-23 — — US disclosed
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2024-01-18 — — US disclosed
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2024-01-18 — — US disclosed
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2024-01-16 — — US disclosed
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2024-01-16 — — US disclosed
CN-117362281-A PI3K inhibitor and preparation method and application thereof 海创药业股份有限公司 2024-01-09 — — CN disclosed
WO-2023212693-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION (US) 2023-11-02 — — WO disclosed
WO-2023081209-A1 PI3K INHIBITORS AND METHODS OF TREATING CANCER ZENO MANAGEMENT, INC. (US) 2023-05-11 — — WO disclosed
WO-2023081209-A1 PI3K INHIBITORS AND METHODS OF TREATING CANCER ZENO MANAGEMENT, INC. (US) 2023-05-11 — — WO disclosed
US-20230096175-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2023-03-30 — — US disclosed
EP-4126851-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION Petra Pharma Corporation (US) 2023-02-08 — — EP disclosed
US-20230017140-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2023-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11878970-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PIK3CA, PIK3R4, PIK3R5 PIK3CA 1/4885PIK3CB 16/4885PIK3CD 6/4885
US-20230096175-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 PIK3CA 1/4885PIK3CB 16/4885PIK3CD 6/4885
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 PIK3CA 1/4885PIK3CB 16/4885PIK3CD 6/4885
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PIK3CA, PIK3R4, PIK3R5 PIK3CA 1/4885PIK3CB 16/4885PIK3CD 6/4885
US-20230017140-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 PIK3CA 1/4885PIK3CB 16/4885PIK3CD 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback